Standard BioTools Files 8-K on Financials

TL;DR

Standard BioTools dropped an 8-K on Oct 30th covering financials - check it for the latest.

AI Summary

Standard BioTools Inc. filed an 8-K on October 30, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company, formerly known as Fluidigm Corp, is incorporated in Delaware and headquartered in South San Francisco, California.

Why It Matters

This 8-K filing provides crucial updates on Standard BioTools' financial performance and operational status, which are important for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant financial and operational information that may impact stock price, requiring careful investor review.

Key Players & Entities

• Standard BioTools Inc. (company) — Registrant
• Fluidigm Corp (company) — Former company name
• October 30, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of incorporation
• South San Francisco, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value per share LAB Nasdaq Glob

Filing Documents

• lab-20241030.htm (8-K) — 48KB
• lab-ex99_1.htm (EX-99.1) — 958KB
• 0000950170-24-119014.txt ( ) — 1186KB
• lab-20241030.xsd (EX-101.SCH) — 51KB
• lab-20241030_htm.xml (XML) — 5KB

02 - Results of Operations and Financial Condition

Item 2.02 - Results of Operations and Financial Condition On October 30, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and nine months ended September 30, 2024. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading "FY 2024 Revenue Outlook" and under the heading "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The information set forth under the heading "Updated FY 2024 Revenue Outlook" and under the heading "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

01 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Standard BioTools Inc., dated October 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2024 STANDARD BIOTOOLS INC. By: /s/ Hanjoon Alex Kim Name: Hanjoon Alex Kim Title: Chief Operating Officer and Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR